Crescendo Biologics Revenue, Valuation, Funding & Investors

GC Corp focuses on healthcare-related activities, including the diagnosis, prevention, treatment, and management of diseases.

Ossium Health is a Denver-headquartered biotech firm operating a cryopreserved bone marrow bank. It supplies immune cells for blood cancer therapies, organ transplant tolerance, and radiation injury repair, partnering with US transplant centers.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.

Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Swedencare AB specializes in pet healthcare. It develops, manufactures partly in its factories, markets, and sells products in the fast-growing market of healthcare products for cats, dogs, and horses. The group has an extensive portfolio of brands and products in various therapy areas, including Animal Pharmaceuticals, Nutravet, NutriScience, Pet MD, Stratford, VetWELL, ProDen PlaqueOff, Rx Vitamins, Riley’s, NaturVet, Pet Organics, Overby Farm, Vet Classics, and Innovet’s brands. Its products are sold to veterinarians, pet stores, and online through a distribution network comprising various subsidiaries and an international network of retailers. The group's operating segments include North America, which generates maximum revenue, Europe, and Production.

Triveni Bio is a Boston-based biotechnology firm developing precision antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven platform to identify novel targets and accelerate proof-of-concept in early drug development stages. Triveni Bio targets autoimmune diseases like inflammatory bowel disease and rheumatoid arthritis with its proprietary discovery engine.

Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Lycia Therapeutics is a South San Francisco-based biotechnology firm advancing lysosomal targeting chimeras platform to degrade disease-causing extracellular proteins. Its LYTAC technology addresses targets inaccessible to traditional drugs, developing therapies for neurodegenerative disorders, cancer, and autoimmune diseases. Founded in 2020, the company raised significant venture funding from investors like Versant Ventures and The Column Group.

Pendulum Therapeutics is a San Francisco-headquartered microbiome therapeutics company developing probiotics via strain-specific DNA sequencing. The firm launched Glucose Control in 2020, a medical probiotic proven in clinical trials to lower A1C and blood sugar spikes for metabolic health. Founded in 2013, Pendulum holds patents in microbiome engineering.

Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Solara Active Pharma Sciences makes active pharmaceutical ingredients, mainly ibuprofen and other generic APIs, for pharma companies worldwide. It runs several manufacturing sites in southern India and supplies regulated and emerging markets. Headquartered in Chennai.